STANDARD BIOTOOLS INC.
Last · NASDAQ$0.632-0.028 (-4.24%)close · yahoo · 18h ago
Market cap$248.11M392.6M sh
P/E · TTM-4.9fwd -63.2 · eps -0.13 · loss
Beta1.35vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.63$1.72
Volume1.2Msession
| Revenue | $85.3M |
|---|---|
| Operating income | $-110.2M |
| Net income | $-74.9M |
| Free cash flow | $-82.6M |
| Operating margin | -129.2% |
| Net margin | -87.8% |
| Return on equity | -17.7% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-03-16
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
Red flags
- Sbc Revenue High — SBC/Revenue 34.7%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -87.8%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -87.1%
- Cash Runway Low — Cash runway ~1.6 years
- Accumulated Deficit High — Accumulated deficit / equity 297%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.02
Est. revenue
18.8M
Earnings transcripts
Press & signals
- GlobeNewswire
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
- GlobeNewswire
Standard BioTools Provides Update on Sale of Mass Cytometry Business
- GlobeNewswire
Standard BioTools Reports Second Quarter 2026 Financial Results
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags